We are live on
!
Find out more
TCM
TimesSquare Capital Management Portfolio holdings
AUM
$5.89B
1-Year Est. Return
28.74%
This Fund
S&P 500
This Quarter
Est. Return
+3.2%
1 Year Est. Return
+28.74%
3 Year Est. Return
+88.57%
5 Year Est. Return
+106.57%
10 Year Est. Return
+590.49%
AUM
$7.19B
AUM Growth
+$18.8M
(+0.26%)
Cap. Flow
-$40.8M
Cap. Flow
% of AUM
-0.57%
Top 10 Holdings %
Top 10 Hldgs %
14.72%
Holding
203
New
14
Increased
81
Reduced
93
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Aptiv
APTV
|
+$67.6M |
| 2 |
Ross Stores
ROST
|
+$52.8M |
| 3 |
Idexx Laboratories
IDXX
|
+$47.9M |
| 4 |
AZPN
Aspen Technology Inc
AZPN
|
+$45.8M |
| 5 |
Legend Biotech
LEGN
|
+$39.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$61M |
| 2 |
TransUnion
TRU
|
+$56.2M |
| 3 |
PACCAR
PCAR
|
+$51.6M |
| 4 |
SAIL
SailPoint Technologies Holdings, Inc. Common Stock
SAIL
|
+$48.3M |
| 5 |
Charles River Laboratories
CRL
|
+$43.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.74% |
| 2 | Industrials | 20.24% |
| 3 | Healthcare | 17.35% |
| 4 | Consumer Discretionary | 13.22% |
| 5 | Financials | 7.8% |
Similar funds
VAM
WAM
JSSH
SC
LIP
CGPCS
CIC
AL
TimesSquare Capital Management's Q3 2022 Portfolio in Review
As of Q3 2022, TimesSquare Capital Management held 203 positions worth $7.19B, up 0.26% from $7.17B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
TimesSquare Capital Management's Q3 2022 filing shows 14 new, 81 increased, 93 reduced and 14 closed positions. Its largest new stake was Aptiv: 704,300 shares worth $55.1M. The largest sale was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $61M.
By sector, the portfolio is most concentrated in Technology at 28% of assets, down from 28% a quarter earlier, followed by Industrials and Healthcare.
- TimesSquare Capital Management's largest Q3 2022 buy was Aptiv: 704,300 shares worth $55.1M.
- TimesSquare Capital Management added most to Idexx Laboratories in Q3 2022, an estimated $47.9M increase.
- TimesSquare Capital Management's biggest Q3 2022 reduction was TransUnion, cutting an estimated $56.2M.
- TimesSquare Capital Management fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2022, selling an estimated $61M.
- TimesSquare Capital Management's ten largest holdings make up 15% of its $7.19B portfolio in Q3 2022.
- TimesSquare Capital Management opened 14 new positions and closed 14 in Q3 2022.
- TimesSquare Capital Management's portfolio value rose 0.26% quarter-over-quarter to $7.19B.
Based on TimesSquare Capital Management's 13F filing for Q3 2022, filed 9 Nov 2022.